SYSTEMS FOR TREATMENT OF PULMONARY INFECTIONS

摘要

1. A system for treating or providing prophylaxis against pulmonary infection in a patient, comprising: (a) a pharmaceutical composition comprising an aminoglycoside in the liposome complex, the composition being an aqueous dispersion, and the lipid component of the liposome is composed of electrically neutral lipids, and ( b) a nebulizer that generates an aerosol of pharmaceutical composition at a rate of more than about 0.53 g per minute, with a mass-median aerodynamic diameter (MMAD) of the aerosol of less than about 4.2 microns, respectively Corollary to measured via Anderson Cascade Impactor (ACI), or less than about 4.9 microns, measured in accordance with a next generation via Impactor (NGI) .2. A system for treating or providing prophylaxis against pulmonary infection, comprising: (a) a pharmaceutical composition containing an aminoglycoside in the liposome complex, the composition being an aqueous dispersion, and the lipid component of the liposome consists of electrically neutral lipids, and (b) a nebulizer, which generates an aerosol of pharmaceutical composition at a rate of more than about 0.53 g per minute, with a fraction of aerosol fines (FPF) of about 64% or more, as measured by ACI, or 51% or more, as measured by NGI. 3. The system of Claim 1, wherein the aminoglycoside is selected from amikacin, apramycin, arbekacin, astromycin, capreomycin, dibecacin, framycetin, gentamycin, hygromycin B, isepamycin, kanamycin, neomycin, netilomycin, paromethomycin, rodreptomycin, rodestreptomycin, rodestreptomycin, rodestreptomycin, rodestreptomycin, rodestreptomycin, rodestreptomycin, rodreptomycin, rodreptomycin, tobramycin, verdamycin, or a combination thereof. 4. System for